<DOC>
	<DOCNO>NCT00217815</DOCNO>
	<brief_summary>The study hypothesis addition Mycograb docetaxel improve outcome advanced carcinoma breast .</brief_summary>
	<brief_title>Preliminary Study Mycograb Docetaxel Advanced Breast Cancer</brief_title>
	<detailed_description>Combination therapy incorporate new agent demonstrate potential improve outcome patient metastatic breast carcinoma . Docetaxel show active drug breast cancer , anthracycline-based chemotherapy combination represent active form therapy generate objective response rate 40-70 % . Mycograb® effective breast carcinoma cell line combination cisplatin , docetaxel anthracyclines ( doxorubicin , daunorubicin ) . We propose Mycograb® bind hsp90 , inhibit hsp90 chaperone function result destabilization key protein include estrogen/steroid receptor , nitric oxide synthase , ras1 , MAP ( Mitogen-activated protein ) kinase , Src , Erb-B2 , ( erythroblastic leukemia viral oncogene homolog 2 ) HER ( human estrogen receptor ) kinases EGFR ( epidermal grow factor receptor ) . Over expression HER2 receptor observe malignancy breast cancer reportedly associate resistance chemotherapeutic agent . Both mature fully mature form receptor depend hsp90 association stability . Inhibition hsp90 function regulate AKT kinase Src kinase non-receptor kinase . Therefore , Mycograb® may use estrogen dependent hormone independent breast cancer . Mycograb® demonstrate anti-tumor activity cell culture . The 50 % cytotoxicity Mycograb® 50 Combination therapy incorporate new agent demonstrate potential improve outcome patient metastatic breast carcinoma . Docetaxel show active drug breast cancer , anthracycline-based chemotherapy combination represent active form therapy generate objective response rate 40-70 % . Mycograb® effective breast carcinoma cell line combination cisplatin , docetaxel anthracyclines ( doxorubicin , daunorubicin ) . We propose Mycograb® bind hsp90 , inhibit hsp90 chaperone function result destabilization key protein include estrogen/steroid receptor , nitric oxide synthase , ras1 , MAP kinase , Src , Erb-B2 , HER kinases EGFR . Overexpression HER2 receptor observe malignancy breast cancer reportedly associate resistance chemotherapeutic agent . Both mature fully mature form receptor depend hsp90 association stability . Inhibition hsp90 function regulate AKT kinase Src kinase non-receptor kinase . Therefore , Mycograb® may use estrogen dependent hormone independent breast cancer . Mycograb® demonstrate anti-tumor activity cell culture . The 50 % cytotoxicity Mycograb® 50 µg/ml ( MCF7 [ Breast cancer cell line designation ] ) . Mycograb® combination docetaxel , doxorubicin cisplatin Herceptin increase cytotoxicity breast cancer cell . It appropriate evaluate apparent tumor response survivor benefit result addition Mycograb® docetaxel contain chemotherapy regimen metastatic recurrent breast cancer patient . ( MCF7 ) . Mycograb® combination docetaxel , doxorubicin cisplatin Herceptin increase cytotoxicity breast cancer cell . It appropriate evaluate apparent tumor response survivor benefit result addition Mycograb® docetaxel contain chemotherapy regimen metastatic recurrent breast cancer patient .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>1 . Patients must female age 18 70 year old . 2 . Patients must histologically clinically confirm metastatic and/or recurrent breast cancer amenable treatment docetaxel . 3 . Patients must presence least one unidimensional measurable lesion minimal lesion size &gt; 20 mm large diameter . 4 . Patients may one previous chemotherapy regimen must receive prior chemotherapy docetaxel . 5 . Patients must hormonal therapy least 2 week prior initiation therapy . 6 . Patients must chemotherapy radiotherapy regimen least 4 week prior initiation chemotherapy . 7 . Patients must life expectancy least 6 month . 8 . Patients must ECOG status 0 , 1 2 . 9 . Patients must willing complete procedure visit outline protocol . 10 . Patients must sign informed consent form . 11 . Patients must negative blood test HIV hepatitis B C. 12 . Female patient child bear potential use effective method contraception . 1 . Patients brain meningeal metastasis . 2 . Patients whose measurable lesion bone . 3 . Patients clinically significant cardiovascular , pulmonary , renal , endocrine , hepatic , respiratory , neurologic , psychiatric , immunologic , gastrointestinal , hematologic , metabolic condition laboratory abnormality opinion investigator make patient unsuitable participation study . 4 . Patients history seizure disorder . 5 . Patients receive treatment investigational drug within precede one month . 6 . Patients pregnant breast feeding .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2008</verification_date>
</DOC>